Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2061452 | 0.79 | MAPT (0.39) | POLBALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL22693083 | 0.77 | POLB (0.44) | POLBALDH1A1L3MBTL1HRH3KDM4E | |
| SCHEMBL22402389 | 0.77 | POLB (0.33) | POLBALDH1A1STING1KDM4EMEN1 | |
| SCHEMBL21455717 | 0.75 | NOTUM (0.45) | POLBKMT2ANPC1 | |
| SCHEMBL762353 | 0.75 | ALDH1A1 (0.45) | POLBALDH1A1L3MBTL1HRH3KMT2A | |
| SCHEMBL13151212 | 0.74 | ALDH1A1 (0.44) | POLBALDH1A1L3MBTL1TRPV1HRH3 | |
| SCHEMBL2061608 | 0.74 | CHRNB4 (0.40) | ALDH1A1MEN1KMT2ANPC1MAPT | |
| SCHEMBL24226100 | 0.73 | ALDH1A1 (0.43) | POLBALDH1A1L3MBTL1TRPV1HRH3 | |
| SCHEMBL24224444 | 0.72 | ALDH1A1 (0.46) | POLBALDH1A1L3MBTL1TRPV1KDM4E | |
| SCHEMBL13656198 | 0.72 | TP53 (0.44) | POLBALDH1A1TRPV1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024901-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2022-01-27 | — | — | US | disclosed |
| US-20200283424-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2020-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283424-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, GIPR | POLB 4812/4885ALDH1A1 564/4885L3MBTL1 3775/4885 |
| US-20220024901-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, GIPR | POLB 4730/4885ALDH1A1 554/4885L3MBTL1 3607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.